AF-130

· Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AF-130, covering 2016-12-06 to 2016-12-06. Get the full timeline:

Most recent: Clinical Trial Update: A Pharmacokinetics Study of AF-130 in Healthy Subjects [Phase 1]